Abstract-The mechanisms underlying the regenerative capacity of endothelial progenitor cells (EPCs) are not fully understood. We hypothesized that biosynthesis of tetrahydrobiopterin is an important mechanism responsible for the stimulatory effects of peroxisome proliferator-activated receptor-␦ (PPAR␦) activation on regenerative function of human EPCs. Treatment of human EPCs with a selective PPAR␦ agonist GW501516 for 24 hours increased the levels of mRNA, protein, and enzymatic activity of GTP cyclohydrolase I (GTPCH I), as well as the production of tetrahydrobiopterin. The effects of GW501516 were mediated by suppression of PTEN expression, thereby increasing phosphorylation of AKT. The AKT signaling also mediated GW501516-induced phosphorylation of endothelial NO synthase. In addition, activation of PPAR␦ significantly enhanced proliferation of EPCs. This effect was abolished by the GTPCH I inhibitor, 2,4-diamino-6-hydroxypyrimidine, or genetic inactivation of GTPCH I with small interfering RNA but not by inhibition of endothelial NO synthase with N G -nitro-L-arginine methyl ester. Supplementation of NO did not reverse 2,4-diamino-6-hydroxypyrimidine-inhibited 5-bromodeoxyuridine incorporation. Furthermore, transplantation of human EPCs stimulated re-endothelialization in a mouse model of carotid artery injury. Pretreatment of EPCs with GW501516 significantly enhanced the ability of transplanted EPCs to repair denuded endothelium. GTPCH I-small interfering RNA transfection significantly inhibited in vivo regenerative capacity of EPCs stimulated with GW501516. Thus, in human EPCs, activation of PPAR␦ stimulates expression and activity of GTPCH I and biosynthesis of tetrahydrobiopterin via PTEN-AKT signaling pathway. This effect enhances the regenerative function of EPCs. (Hypertension. 2011;58:287-294.) • Online Data Supplement
xisting evidence indicates that activation of peroxisome proliferator-activated receptor-␦ (PPAR␦) in the endothelium stimulates angiogenesis, 1,2 protects endothelial cells from apoptosis, 3 and suppresses atherosclerosis. 4 Previous studies from two different groups including ours have demonstrated that activation of PPAR␦ plays an important role in the angiogenic function of human EPCs. 5, 6 However, the underlying mechanisms are not well defined.
Tetrahydrobiopterin (BH4), an essential cofactor of NO synthase (NOS), is required for allosteric and redox activation of all three isoforms of NOS. 7, 8 GTP cyclohydrolase I (GTPCH I) is the rate-limiting enzyme responsible for de novo synthesis of BH4 from GTP. 7, 8 Previous studies have also suggested that BH4 plays a critical role in regulating proliferation of several different cell types, including endothelial cells 9 and hematopoietic cells. 7, 10, 11 Interestingly, high levels of BH4 are detected in tissues enriched in progenitor cells, including spleen and bone marrow. 12 However, the role of BH4 in biological function of endothelial progenitor cells is unknown. We hypothesized that biosynthesis of BH4 is an important mechanism responsible for the stimulatory effects of PPAR␦ activation on regenerative function of human EPCs. We provide compelling evidence that activation of PPAR␦ stimulates GTPCH I expression and biosynthesis of BH4, which, in turn, enhances the ability of EPCs to repair injured endothelium.
Methods
For an expanded Methods section and description for measurements of biopterin levels and GTPCH I activity, GTPCH I knockdown by
Isolation, Culturing, and Phenotyping of Endothelial Progenitor Cells
The collection and use of human blood samples was approved by the institutional review board at the Mayo Clinic. Late outgrowth EPCs (also classified as endothelial colony-forming cells 5, 13, 14 ) were outgrown after 2 to 3 weeks of culturing of mononuclear cells isolated from the peripheral blood of 18 healthy male subjects (46Ϯ2 years old) as described previously by our group. 5, 13 
Western Blot Analysis
EPCs were incubated in endothelial basal medium 2 containing minimum (0.5% or 2.0%) FBS and indicated treatments for 10 minutes to 24 hours. Western blotting was performed as described previously. 5, 13 Rabbit antibodies against AKT (protein kinase B), phospho-AKT (Ser473), phosphatase and tensin homologue deleted on chromosome 10 (PTEN), phosphoinositide-dependent protein kinase 1 (PDK1), and phospho-PDK1 (Ser241) were obtained from Cell Signaling Technology. Mouse antibodies against endothelial NO synthase and phosphoendothelial NO synthase (Ser1177) were purchased from BD Transduction Laboratories. Goat antibodies against integrin-linked kinase and actin were obtained from Santa Cruz Biotechnology.
Mouse Model of Vascular Injury and Endothelial Repair
All of the experimental protocols were approved by the institutional animal care and use committee of the Mayo Clinic. Athymic (nude) male mice (strain: B6Cg-Foxn1 nu ; 14 to 16 week old) were obtained from the Jackson Laboratory. Animals were housed in a pathogenfree environment with free access to normal rodent chow and water. Splenectomy 15 and electric current-induced carotid injury 16 were performed as described previously.
Statistical Analysis
Data are presented as meanϮSEM. Differences between mean values of multiple groups were analyzed using 1-way ANOVA followed by the Tukey test (SigmaStat 2.03 for Windows). Comparison between 2 groups was made using Student t test. PϽ0.05 was considered statistically significant.
Results

Activation of PPAR␦ Upregulates GTPCH I Expression in EPCs
Interestingly, human EPCs had significantly higher levels of GTPCH I activity and BH4, as compared with human umbilical vein endothelial cells ( Figure S1A and S1B, available in the online Data Supplement). There were no significant differences in levels of BH2 and the percentage of (BH4/[BH4ϩBH2])ϫ100 between EPCs and human umbilical vein endothelial cells ( Figure S1C and S1D). Treatment of EPCs with the PPAR␦-specific agonist GW501516 (3 mol/L) for 24 hours significantly increased BH4 production and GTPCH I activity ( Figure 1A and 1B) . This was associated with increased expression of GTPCH I mRNA and protein ( Figure 1C and 1D) .
Role of PTEN-AKT Signaling in the Stimulatory Effect of PPAR␦ Activation on Production of BH4
Because phosphorylation of AKT has been shown to increase GTPCH I activity in mouse aorta, 17 we first examined whether AKT signaling is involved in the upregulation of GTPCH I induced by GW501516. Incubation of EPCs with GW501516 (3 mol/L) for 24 hours decreased protein levels of PTEN (a negative regulator of the phosphoinositide 3-kinase [PI3K]-AKT pathway 18 ) and increased phosphorylation of AKT in a concentration-dependent manner ( Figure  2A and 2B). Suppression of PTEN by activation of PPAR␦ did not occur at the early time points of the treatment (5 minutes to 3 hours; Figure 2C ). Moreover, downregulation of PTEN and phosphorylation of AKT followed a similar time course ( Figure 2C ), indicating that suppression of PTEN caused phosphorylation of AKT in EPCs. We also ruled out the possibility that downregulation of PTEN was mediated by GW501516-induced activation of AKT-nuclear factor B. 19 As shown in Figure 2D , inhibition of AKT signaling by the PI3K inhibitor LY294002 did not affect the suppression of PTEN by GW501516. To verify the selectivity of GW501516, EPCs were treated with a specific antagonist of PPAR␦, GSK0660 (2 mol/L). 20 As shown in Figure 2E and 2F, GKS0660 abolished the effects of GW501516 on expression of PTEN and phosphorylation of AKT. Furthermore, LY294002 or GSK0660 abolished the stimulatory effect of GW501516 on expression of GTPCH I ( Figure 2G ). LY294002 blocked GW501516-induced BH4 production ( Figure 2H ). Therefore, these results suggest that activation of PPAR␦ increases GTPCH I expression and BH4 biosynthesis via PTEN-AKT pathway.
Because both PDK1 and integrin-linked kinase (both of which activate AKT by phosphorylation of AKT at serine 473) 21 have been established as the target genes for PPAR␦ in mouse keratinocytes, 21 we also examined expressions of these proteins. GW501516 did not significantly affect the protein levels of PDK1, phospho-PDK1, and integrin-linked kinase ( Figure 2I ), thus demonstrating that, in human EPCs, activation of PPAR␦ selectively affects the PTEN-AKT pathway.
Activation of PPAR␦ Stimulates Phosphorylation of Endothelial NO Synthase
Similar to changes in the time course of PTEN and phospho-AKT expressions, GW501516 induced phosphorylation of endothelial NO synthase (eNOS) 24 hours after the treatment but not during the early periods of the treatment (10 minutes to 3 hours; Figure 3A and 3B). PI3K inhibitors LY294002 and wortmannin diminished the stimulatory effects of GW501516 on phosphorylation of eNOS ( Figure 3C ). These results indicate that phosphorylation of eNOS induced by activation of PPAR␦ is mediated by the PI3K-AKT pathway.
Activation of PPAR␦ Increases Proliferation of EPCs
Our previous studies 5 suggest that EPC mitogenesis depends on PPAR␦ signaling. However, the underlying mechanisms are unknown. In the present study, activation of PPAR␦ with GW501516 significantly increased cell number and BrdU incorporation ( Figure 4A and 4B). To verify the effect of 2,4-diamino-6-hydroxypyrimidine (DAHP) (a GTPCH I inhibitor) on the intracellular BH4 level, EPCs were treated with DAHP (5 mmol/L) for 42 hours. DAHP treatment abolished production of BH4 (1.11Ϯ0.74 and 0 pmol/L per milligram in control cells and treated cells, respectively; nϭ3; PϽ0.05). Under basal conditions, DAHP significantly reduced cell number and BrdU incorporation ( Figure 4A and 4B). In addition, DAHP blocked GW501516-induced cell growth and BrdU incorporation ( Figure 4A and 4B). In contrast, inhibition of NOS with N G -nitro-L-arginine methyl ester (L-NAME; 1 mmol/L) did not significantly affect cell growth under basal conditions or during the treatment with GW501516 ( Figure 4A ). The inhibitory effect of DAHP on GW501516-induced BrdU incorporation was not reversed by supplementation of NO using DETA NONOate ( Figure 4B ). Downregulation of GTPCH I by siRNA ( Figure S2 ) also significantly reduced cell number ( Figure 4C ; no significant floating cells observed). GTPCH I-siRNA transfection inhibited GW501516-stimulated cell growth ( Figure 4C ). These results suggest that GW501516-enhanced cell proliferation is primarily dependent on BH4 and independent of NO production.
To test whether intracellular production of ROS is involved in the effects of GW501516, we measured oxidation of CM-H 2 DCF-DA in EPCs. Treatment of EPCs with L-NAME did not affect ROS production ( Figure S3 ), indicating that uncoupling of eNOS is not a major source of ROS under basal culture conditions. Incubation of EPCs with GW501516 (3 mol/L) for 24 hours did not change ROS levels ( Figure  S3 ), suggesting that the stimulatory effect of GW501516 on cell proliferation is not mediated by change in intracellular concentration of ROS.
Activation of PPAR␦ Increases Migration of EPCs
Activation of PPAR␦ with GW501516 in EPCs significantly increased vascular endothelial growth factor (VEGF)-induced migration ( Figure S4A through S4C and S4G). Interestingly, both DAHP and L-NAME inhibited GW501516-enhanced cell migration ( Figure S4A through S4G), thus suggesting that both BH4 and NO mediate stimulatory effects of GW501516 on cell migration. Supplementation of EPCs with sepiapterin (1 mol/L) 22 attenuated the inhibitory effect of L-NAME on cell migration, indicating that BH4-mediated cell migration augmented by GW501516 is partially NO independent.
Activation of PPAR␦ in EPCs Enhances Re-Endothelialization Stimulated by EPCs
Because GW501516 stimulated EPCs mitogenesis and migration, we examined whether activation of PPAR␦ in EPCs enhances the ability of EPCs to repair the injured endothelium in vivo. Three days after carotid artery injury in nude mice, injected EPCs significantly augmented endothelial repair ( Figure 5A and 5B). Injection of EPCs pretreated with GW501516 (3 mol/L for 24 hours) further enhanced the ability of EPCs to repair the endothelium ( Figure 5A and 5B). Moreover, transfection of EPCs with GTPCH I-siRNA significantly reduced the regenerative capacity of EPCs pretreated with GW501516 compared with EPCs transfected with control-siRNA (Ct-siRNA) ( Figure 5C ).
Discussion
We report several novel findings: (1) in human EPCs, activation of PPAR␦ increases BH4 production and stimulates phosphorylation of eNOS; (2) the effects of PPAR␦ activation are mediated by decreased expression of PTEN and subsequent activation of PI3K-AKT signal transduction pathway; (3) intracellular levels of BH4 are a critical determinant of GW501516-enhanced proliferation and migration of EPCs; (4) activation of PPAR␦ in EPCs augments re-endothelialization stimulated by EPCs; and (5) production of BH4 in EPCs contributes to the in vivo regenerative capacity of EPCs stimulated by GW501516.
PPARs (␣, ␥, and ␦) belong to the nuclear hormone receptor family of ligand-activated transcription factors. All 3 PPAR subtypes modulate genes that regulate lipid and glucose metabolism, as well as gene expression in vascular cells, although they exert significant differences in their ligand and gene specificities. 23 Compared with the other 2 subtypes, the biological role and function of PPAR␦ are relatively unclear. 24 Previous studies have established that PPAR␦ is almost ubiquitously expressed through the body, including cardiovascular system. 23, 24 Activation of PPAR␦ suppresses development of atherosclerosis by elevating high-density lipoprotein 25 and by inhibiting inflammatory processes. 26, 27 Recently, the angiogenic and endothelial protective effects of PPAR␦ have also been recognized. [1] [2] [3] However, the roles of PPAR␦ in regenerative function of EPCs are less explored. 5, 6 The results of the present study offer new insights into an important role of BH4 in functional integrity of human EPCs. Our findings demonstrate that activation of PPAR␦ significantly increases intracellular concentration of BH4. This effect is caused by an AKT-dependent increase in expression and activity of GTPCH I, a rate-limiting enzyme in the production of BH4. 8 The regulation of AKT signaling by PPAR␦ activation can be explained by genomic and nongenomic mechanisms. 6, 19, 21 In the case of genomic activation of AKT, PPAR␦ ligands regulate several proteins upstream of AKT, including PDK1, integrin-linked kinase, and PTEN. 21 PTEN (also named mutated in multiple advanced cancers 1; MMAC1), is a tumor suppressor gene. It antagonizes the PI3K pathway by dephosphorylating the signaling lipid phosphatidylinositol 3,4,5-triphosphate. 18 To our knowledge, our findings provide the first demonstration of a link between PTEN signaling and . Cell numbers were counted using a cytometer. nϭ6 to 18, *PϽ0.05, compared with control, N G -nitro-L-arginine methyl ester (L-NAME) treated, DAHP treated, and DAHPϩGW501516-treated groups; **PϽ0.05, compared with control and L-NAME groups; ***PϽ0.05, compared with control group. B, After cells were treated with GW501516, DAHP, and EDTA NONOate for 15 hours, cells were labeled with bromo-2Ј-deoxyuridine (BrdU) for 24 hours in the presence of previous treatments. nϭ11, *PϽ0.05, compared with control; **PϽ0.05, in comparison with all of the other groups. C, EPCs were transfected with 30 nmol/L of GTP cyclohydrolase I (GTPCH I)-small interfering RNA (siRNA) or control-siRNA (Ct-siRNA) for 24 hours, and cells were then subjected to assay for cell growth under the treatment of GW501516 (3 mol/L) for 72 hours as described in A. nϭ9, *PϽ0.05, compared with all of the other groups; **PϽ0.05, compared with control.
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PPAR␦ activation in human EPCs. Existing evidence suggests that regulation of PTEN expression by PPAR␦ may also be controlled by indirect mechanisms, 19, 21 such as activation of the PI3K-AKT-nuclear factor B (p65) pathway 19 ; however, our data ( Figure 2D ) ruled out this possibility. Previous studies also indicate that treatment with GW501516 may also phosphorylate AMP-activated protein kinase. 28 Whether this pathway may contribute to the observed downregulation of PTEN remains to be determined. It has been reported that activation of PPAR␦ with a low concentration of GW501516 (0.03 to 0.10 mol/L) increases release of VEGF from human endothelial cells 1 and stimulates vascular smooth muscle cells to express transforming growth factor-␤1. 29 Both of these peptides can stimulate phosphorylation of AKT. 30 We have examined the protein levels of VEGF and transforming growth factor-␤1 in the supernatant of cultured EPCs, using RayBio Human Cytokine Antibody Array 5. We did not find changes in production of angiogenic factors, including VEGF and transforming growth factor-␤1, from EPCs treated with GW501516 (0.2 mol/L) for 24 hours (data not shown). However, we cannot rule out the possibility that VEGF and/or transforming growth factor-␤1 are elevated in response to a higher concentration of GW501516 used in the present study.
GTPCH I is regulated on both transcriptional and posttranslational levels. 8 Several pathways, such as IB kinase (IK)-nuclear factor B, Jak2-Stat1, 31 RAS-mitogen-activated protein kinase kinase, 32 and protein kinase A 33 have been documented to play a role in the induction of GTPCH I expression. In mouse macrophages, PI3K-AKT signaling also partially contributes to lipopolysaccharide and interferon-␥-stimulated GTPCH I gene expression 34 ; however, in mouse aorta, erythropoietin-induced production of BH4 caused by activation of AKT is not associated with changes in GTPCH I expression. 17 The results of the present study provide evidence that, in human EPCs, GW501516-induced GTPCH I expression is mediated by activation of the PI3K-AKT pathway. Because PI3K-AKT can activate transcriptional factors nuclear factor B 19 and Stat1, 35 it is conceivable that they may be potential downstream targets of AKT for promoting GTPCH I expression.
BH4 is a natural cofactor of aromatic amino acid hydroxylases and NOS isoforms. 7 Earlier studies have also established that BH4 is an essential growth factor for Crithidia fasciculata. 7 The role of BH4 as a growth factor is conserved in the higher organisms. Indeed, BH4 is required for DNA synthesis and mitogenesis of erythroid cells 11 and T cells. 10 In addition, treatment with BH4 or sepiapterin stimulates proliferation of PC12 cells and tumor cells. 36 The molecular mechanisms underlying these effects are not clear; however, it appears that the BH4-induced cell proliferation of PC12 cell is not dependent on NO production. 36 This observation is consistent with our findings, as well as with findings reported by Arnal et al. 37 Indeed, in the present study, we observed a strikingly higher level of BH4 in EPCs as compared with human umbilical vein endothelial cells. This high basal level of BH4 is critical for EPC growth, as shown in Figure 4 . In contrast to the inhibition of BH4 production, inhibition of NOS did not affect EPC proliferation, thus, suggesting that production of NO may not affect EPC proliferation under basal conditions. Moreover, GW501516-induced mitogenesis was also BH4 dependent, because inhibition of GTPCH I via both pharmacological and genetic approaches attenuated the effect of GW501516 on cell growth and DNA incorporation. On the other hand, inhibition of NOS did not affect GW501516-induced mitogenesis, whereas supplementation with an NO donor did not reverse DAHP-suppressed incorporation of DNA stimulated by GW501516. These observa- tions further support our conclusion that NO production is not a major determinant of EPC proliferation stimulated by activation of PPAR␦.
Our findings that L-NAME did not affect ROS production indicate that eNOS is not uncoupled in cultured EPCs. This is in line with the observation that EPCs have high BH4 biosynthesis ( Figure S1 ) and low eNOS expression. 13 Thus, it is unlikely that prevention of eNOS uncoupling plays an important role in the mitogenic effect of GW501516. Our findings support the concept that the enhanced mitogenesis of EPCs caused by activation of PPAR␦ depends on biosynthesis of BH4. The exact mechanisms responsible for BH4-dependent growth of EPCs remain to be determined.
In endothelial cells, NO plays an important role in cell migration by stimulating cell podokinesis, enhancing the expression of ␣ v ␤ 3 , and increasing dissolution of the extracellular matrix. 38 In the present study, cell migration was significantly increased by GW501516 treatment. This effect depended on the availability of both BH4 and NO. Activation of PPAR␦ may increase NO production by augmentation of phosphorylation of eNOS and BH4 production. Interestingly, supplementation of sepiapterin attenuated the L-NAMEsuppressed cell migration, indicating that BH4 may also stimulate migration in part by mechanisms independent of NO production. We also wish to point out that increased proliferation and migration of EPCs stimulated by GW501516 may enhance incorporation of EPCs into the denuded carotid artery, thus contributing to accelerated repair of the injured endothelium.
Our in vivo analysis of endothelial repair in the mouse model of vascular injury confirmed the results of previous studies demonstrating that transplantation of EPCs accelerates repair of the denuded endothelium. 39 Consistent with a previous report, 39 a regular wave-like pattern of endothelial repair was detected in the injured carotid artery. In contrast, in our previous study, 40 intraluminal delivery of EPCs into an injured rabbit carotid artery resulted in a sporadic pattern of re-endothelialization. The exact reasons for a differential pattern in endothelial repair are unknown but could be related to different cell delivery techniques or different species used. Most importantly, the in vivo studies support the view that activation of PPAR␦ enhances the regenerative capacity of human EPCs. Our study is the first to demonstrate that treatment of cultured EPCs with a PPAR␦ agonist significantly enhances their ability to exert a beneficial effect on re-endothelialization. These findings support the concept that therapeutic application of PPAR␦ agonists may include vascular protection in conditions associated with injury and loss of endothelium. Whether these beneficial effects of PPAR␦ agonists may also affect pathogenesis of hypertension is not clear and remains to be determined.
Perspectives
PPAR␦ agonists are currently in clinical development as drugs for treatment of dyslipidemia. 41 However, preclinical studies suggest that these compounds exert a number of beneficial effects in the cardiovascular system independent of their effect on lipid metabolism. Indeed, previous studies demonstrated that treatment with PPAR␦ agonists prevented the development of angiotensin II-accelerated atherosclerosis. 26 In the present study, we provide evidence that GW501516 increases expression and activity of GTPCH I and eNOS in cultured human EPCs. Most notably, activation of PPAR␦ significantly enhances mitogenesis and migration of EPCs, as well as the ability of EPCs to repair endothelium in vivo. Intracellular levels of BH4 in EPCs appear to be a critical determinant of the therapeutic effect of EPCs. These observations establish previously unrecognized beneficial effects of PPAR␦ agonists and suggest that PPAR␦ is an attractive target in the prevention and treatment of cardiovascular diseases associated with injury and loss of endothelium.
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Isolation, Culturing, and Phenotyping of Endothelial Progenitor Cells
The collection and use of human blood samples was approved by the Institutional Review Board at the Mayo Clinic. Late outgrowth EPCs (also classified as endothelial colony-forming cells) (1-3), were outgrown after 2 to 3 weeks of culturing of mononuclear cells isolated from the peripheral blood of 18 healthy male subjects (46±2 years old) as previously described by our group (1,2) . Briefly, human blood mononuclear cells were isolated by density gradient centrifugation with FicollPaque Plus (Amersham Biosciences Corp.), and plated at a density of ~ 2 ×10 7 cells /well on 6-well plates coated with human fibronectin (R & D Systems Inc.). Cells were cultured in endothelial growth medium-2 (EGM-2, Lonza), which was composed of endothelial cell basal medium-2 (EBM-2, a serum-and growth factor-free medium), 2% fetal bovine serum (FBS), fibroblast growth factor, vascular endothelial growth factor, insulin-like growth factor, epidermal growth factor, ascorbic acid, hydrocortisone, and heparin. The medium was refreshed every 48 h. The outgrowth EPCs colonies appeared after 2-3 weeks of culture. The phenotypic characteristics of EPCs [positive for endothelial cell surface antigens (Flk1, CD31, and VE-cadherin) and the hematopoietic progenitor marker CD34, and negative for myelomonocytic cell marker CD14, assayed by fluorescenceactivated cell sorting analysis] were the same as those described in our previous studies (1) . In parallel, human umbilical vein endothelial cells (HUVECs, Lonza) were cultured in EGM-2. All experiments were performed using cells cultured from passages 4 to 7.
Western Blot Analysis
EPCs were incubated in endothelial basal medium2 (EBM2) containing minimum (0.5% or 2%) fetal bovine serum (FBS) and indicated treatments for 10 min-24 h. Western blotting was performed as previously described (1, 2) . Rabbit antibodies against AKT (protein kinase B), phospho-AKT (Ser473), phosphatase and tensin homologue deleted on chromosome ten (PTEN), phosphoinositide-dependent protein kinase 1 (PDK1), and phospho-PDK1 (Ser241) were obtained from Cell Signaling Technology. Mouse antibodies against eNOS, and phospho-eNOS (Ser1177) were purchased from BD Transduction Laboratories. Goat antibodies against integrin-linked kinase (ILK), and actin were obtained from Santa Cruz Biotechnology. A polyclonal anti-human GTPCH I antibody was generated in rabbits using peptide ERDPPRPGPSRPAEK of human GTPCH I (gene accession: NM_001024071), by Invitrogen. The specificity of the antibody was verified in cells overexpressed with human GTPCH I (data not shown). Protein expression was normalized to actin.
Measurements of Biopterin Levels and GTPCH I Activity
Reverse-phase high-performance liquid chromatography (HPLC) was employed to determine levels of BH4 and 7,8-dihydrobiopterin, as well as GTPCH I activity as previously described (4). Briefly, after EPCs were treated with GW501516 (Alexis Biochemical or Cayman Chemical) and/or LY294002 (Cayman Chemical) for 24 h, cells were collected on ice in lysis buffer (pH 7.5) containing 50 mmol/L Tris·HCl, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 0.1% SDS, 0.1% deoxycholate, 1% IGEPAL, and mammalian protease inhibitor cocktail (Sigma), and sonicated 3 x 10 seconds using Vibra Cell ultrasonic processor (Sonics and Materials In.). The total cell lysates were subject to assaying biopterin levels and GTPCH I activity using reverse-phase HPLC (Beckman Coulter, Fullerton, CA) with a fluorescence detector (Jasco). Data were collected and analyzed by 32 Karat chromatography software (Beckman Coulter) and normalized against protein levels. BH 4 content was calculated from the difference in biopterin levels after acid and base oxidations.
GTPCH I Knockdown by Small Interfering RNA (siRNA)
Experiments were performed as described in our previous studies (1) . GTPCH I-siRNA targeting human GTPCH I mRNA was obtained from Dharmacon. The target sequence is 5'UUGCGAGGAUUGUAGAAAU3'. The target sequence of the negative control siRNA duplex oligonucleotides (Ct-siRNA) was 5' UUCUCCGAACGUGUCACGU3'. For in vivo experiments, another Ct-siRNA (5'CGAACUCACUGGUCUGACC3') (Santa Cruz) was also used. EPCs were transfected with 30 nmol/L (optimized concentration) siRNA by use of Lipofectamine 2000 (Invitrogen), according to manufacture's protocol. Fresh EGM-2 was added 6.5 h after the transfection, and the cells were used for further studies 24 h after transfection.
Quantitative Real-Time Polymerase Chain Reaction (PCR) and RT-PCR
Real time PCR was performed as previously described (5) . After EPCs were treated with GW501516 for 19 h, total cellular RNA was isolated from EPCs using RNeasy Plus Mini kit (Qiagen). Reverse transcription of RNA to cDNA was performed using SuperScript III First-Strand Synthesis System kit (Invitrogen). The amounts of human GTPCH I mRNA and internal control GAPDH mRNA were determined (in triplicate for each sample) using iCycler IQ Real Time Detection System (Bio-Rad). The target DNA was amplified by 40 cycles: denaturation for 30 seconds at 94 0 C, annealing for 30 seconds at 57 0 C, and extension for 30 seconds at 74 0 C.The primers (6) corresponding to human GTPCH I mRNA are forward (5'GCCATGCAGTTCTTCACCAA3') and reverse (5'AGGCTTCCGTGATTGCTACA3'). Internal control GAPDH mRNA was amplified with forward (5'ACCACAGTCCATGCCATCACTGCC3') and reverse (5'ACCAGGAAATGAGCTTGACAAAGT3') primers. The data were then quantified with the comparative C T method for relative gene expression. C T is defined as the PCR cycle at which the fluorescent signal crosses a particular threshold, with the numerical value of the C T being inversely related to the amount of amplicon in the reaction. The data were then normalized to the C T value of an internal control GAPDH: C T = C T for GTPCHI -C T for GAPDH. The amount of gene of interest relative to internal control GAPDH was then calculated as 2 -ΔCT . RT-PCR was performed to monitor the inhibitory effect of GTPCH I-siRNA. After transfection of EPCs with 30 nmol/L Ct-siRNA or GTPCH I-siRNA for 24h, mRNA was isolated and reversetranscripted using SuperScript III First-Strand Synthesis System kit (Invitrogen). The cDNA was then amplified using above primers. Eighteen cycles of amplification were performed under the same conditions described above.The PCR products were visualized on an agarose gel.
Bromo-2'-deoxyuridine (BrdU) Incorporation Assay
Experiments were performed as described in our previous studies (1). Briefly, EPCs (4,000 cells/well) were seeded on 96-well plates (experiments were performed in triplicate). Six h after, EPCs were incubated with 5%FBS + EBM2 (200 µl/well) + treatments for 15 h. Then the cells were labeled with 10µmol/L BrdU labeling solution (Cell Proliferation ELISA kit, Roche Applied Science) in the presence of treatments for 24 h. Cells were fixed and exposed to anti-BrdU and substrate solutions. The reaction product was quantified by measuring absorbance with a microplate reader (Model 680XR, Bio-Rad). 2,4-diamino-6-hydroxypyrimidine (DAHP, a GTPCH I inhibitor) and Diethylenetriaamine NONOate (DETA NONOate, a NO donor) were purchased from Cayman Chemical.
Migration Assay
The migratory function of EPCs was evaluated using a modified Boyden chamber (Transwell Permeable Supports, Corning In.) assay (7) . In brief, EPCs (2 x 10 4 /well) were seeded (in duplicate) in the upper chamber of 24-well Transwell plates with polycarbonate membrane (8 μm Figure S1 Figure S1. Characterization of GTPCH I enzymatic activity and biopterin levels in human EPCs and HUVECs. Cell were incubated in EBM2 containing 0.5%FBS for 24 h, cells were collected and immediately subjected to measurement of GTPCH I activity and biopterin. A: n=4-5, *P<0.05, compared to HUVECs. B: n=4-6, *P<0.05, compared to HUVECs. C and D: n=4-6. 
